ATARA Biotherapeutics (ATRA) Misses Q3 EPS by 9c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q3 EPS of ($0.88), $0.09 worse than the analyst estimate of ($0.79).

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Bernstein SocGen Group Upgrades X-Fab Silicon Foundries SE (XFAB:FP) to Outperform
• Pfizer lung cancer drug misses survival goal in Phase 3 trial